Type-1 histiocytosis response to 90Y-lanreotide.
Department of Clinical Oncology, Royal Free and University College Medical School, London, UK.
Nicholas
N
Turner
Peter
P
Amlot
Andrew
A
Platts
Alison
A
Jones
John
J
Buscombe
D000328:Adult; D005260:Female; D006571:Heterocyclic Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D006646:Histiocytosis, Langerhans-Cell / Q000532:radiotherapy*; D006801:Humans; D010456:Peptides, Cyclic / Q000009:adverse effects / Q000627:therapeutic use*; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*
D006571:Heterocyclic Compounds; D010456:Peptides, Cyclic; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C116408:yttrium 90-DOTA-lanreotide